UK Markets open in 3 hrs 8 mins

Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
667.20+9.20 (+1.40%)
At close: 4:59PM CEST
Full screen
Previous close658.00
Open658.00
Bid667.20 x 0
Ask0.00 x 0
Day's range654.20 - 668.20
52-week range406.90 - 684.50
Volume1,417,277
Avg. volume1,904,099
Market cap1.532T
Beta (5Y monthly)0.27
PE ratio (TTM)36.26
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield9.35 (1.45%)
Ex-dividend date16 Aug 2021
1y target estN/A
All
News
  • Globe Newswire

    Novo Nordisk A/S – Share repurchase programme

    Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 18 October 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period be

  • Globe Newswire

    Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 10 August 2021

    Bagsværd, Denmark, 11 August 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their a

  • Globe Newswire

    Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 9 August 2021

    Bagsværd, Denmark, 10 August 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their a